Table 3.

Effect of Race on Dose‐Normalized PK Parameters ^a (Part A, PK Population ^b )

Parameter Single Dose (Day 1)	Japanese n = 25	White n = 24	Ratio of Means (90% CI) for All Participants
Cmax, (ng/mL)/mg	6.1	6.9	88.1 (74.7‐103.9)
AUCτ, (ng ‧ h/mL)/mg	62.5	75.4	82.9 (72.3‐95.1)
AUClast, (ng ‧ h/mL)/mg	94.0	118.8	79.2 (67.5‐92.8)
AUC∞, (ng ‧ h/mL)/mg	103.9	133.9	77.6 (65.1‐92.6)

Multiple Dosing (Day 30)	n = 23	n = 24
Cmax, (ng/mL)/mg	8.5	10.6	80.9 (68.6‐95.3)
AUCτ, (ng ‧ h/mL)/mg	107.6	144.8	74.4 (60.3‐91.8)
AUClast, (ng ‧ h/mL)/mg	172.9	243.8	70.9 (55.8‐90.1)
AUC∞, (ng ‧ h/mL)/mg	194.9	285.4	68.3 (52.7‐88.6)

AUC_∞, area under the plasma concentration–time curve from time 0 to infinity; AUC_τ, area under the plasma concentration–time curve over the dosing interval; AUC_last, area under the plasma concentration–time curve from time 0 to the last time with quantifiable concentration; C_max, maximum plasma concentration; PK, pharmacokinetic.

Data are expressed as geometric least squares mean.

^a Analysis based on data pooled from all 3 brensocatib dose groups.

^b The PK population for part A included 49 participants (25 Japanese, 24 White) who received brensocatib and had evaluable PK data.